Want to see SE:ONCO full AI Analyst Report?
ONCO Stock Chart & Stats
kr1.65
kr0.04(2.18%)
At close: 4:00 PM EDT
kr1.65
kr0.04(2.18%)
Day’s Range― - ―
52-Week Rangekr1.26 - kr6.18
Previous CloseN/A
Volume1.31M
Average Volume (3M)4.60M
Market Cap
kr803.14M
Enterprise Valuekr595.78M
Total Cash (Recent Filing)kr157.61M
Total Debt (Recent Filing)kr135.17M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding381,357,760
10 Day Avg. Volume5,653,458
30 Day Avg. Volume4,602,999
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)kr127.67M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthStrong year-over-year sales growth indicates increasing commercial adoption of Pepaxti across Europe. If this trajectory continues, expanding revenue can improve operating leverage, support reinvestment in the pipeline, and move the company closer to its stated goal of covering operating expenses.
Exceptional Gross MarginA 98% gross margin provides substantial economic leverage as product sales scale, because most incremental revenue can contribute toward operating expenses and development investment. The improving EBIT loss also suggests that growth and cost discipline are beginning to translate into better underlying operating performance.
European Commercial Opportunity And ExclusivityEstablished patient treatment across Europe demonstrates that Pepaxti has moved beyond development into commercial use. Long market exclusivity through 2037 can protect the product’s competitive position and give Oncopeptides a durable period to build prescriber adoption, sales coverage, and recurring product revenue.
Bears Say
Persistent Operating LossesThe company remains materially loss-making despite improved revenue and EBIT, so commercial growth has not yet reached the scale needed to support the cost base. Continued losses can delay self-funded expansion and leave results dependent on successful execution, further sales growth, or additional financing.
High Leverage And Cash ConsumptionHigh leverage relative to the equity base reduces financial flexibility while the business continues to consume substantial cash. Until operating losses narrow and cash flow turns positive, debt obligations and funding needs may constrain investment choices and increase sensitivity to setbacks in commercial or regulatory execution.
Uneven Commercial ExecutionCommercial progress is not uniform across markets, with healthcare-access disruption and intense competition affecting Spain and delays slowing Japan’s partnering path. These issues can defer regional revenue contributions, complicate launch planning, and make the route to sustained cash-flow positivity less predictable.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.18 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr803.14M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Nov 05, 2026 which is in 29 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Aug 27, 2026. The company reported -kr0.144 earnings per share for the quarter.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 381,357,760 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.144 in its last earnings report. Following the earnings report the stock price went up 20.447%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
Immunicum AB
―
Cantargia AB
―
Sprint Bioscience AB
―